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Abstract
Purpose of Review A major cause of visual disorders is dys-
function and/or loss of the light-sensitive cells of the retina,
the photoreceptors. To develop better treatments for patients,
we need to understand how inherited retinal disease mutations
result in the dysfunction of photoreceptors. New advances in
the field of stem cell and gene editing research offer novel
ways to model retinal dystrophies in vitro and present oppor-
tunities to translate basic biological insights into therapies.
This brief reviewwill discuss some of the issues that should
be taken into account when carrying out disease modelling
and gene editing of retinal cells. We will discuss (i) the use
of human induced pluripotent stem cells (iPSCs) for disease
modelling and cell therapy; (ii) the importance of using iso-
genic iPSC lines as controls; (iii) CRISPR/Cas9 gene editing
of iPSCs; and (iv) in vivo gene editing using AAV vectors.
Recent Findings Ground-breaking advances in differentiation
of iPSCs into retinal organoids and methods to derive mature
light sensitive photoreceptors from iPSCs. Furthermore, sin-
gle AAV systems for in vivo gene editing have been devel-
oped which makes retinal in vivo gene editing therapy a real
prospect.
Summary Genome editing is becoming a valuable tool for
disease modelling and in vivo gene editing in the retina.
Keywords Vision impairment . Retina . Photoreceptors .
Induced pluripotent stem cells . Diseasemodelling . Gene
editing
Introduction
Inherited Retinal Degenerative Diseases
Vision impairment is a global health issue estimated to affect
more than 285 million people worldwide [1]. Over 50% of all
visual impairment cases in the developing world are the result
of dysfunction and/or loss of photoreceptors, a specialized
type of neuron that performs the essential first step in
transforming light into vision [2]. Inherited retinal diseases
such as retinitis pigmentosa (RP), Leber congenital amaurosis
(LCA), Stargardt disease, as well as more complex and het-
erogeneous retinal diseases such as age-related macular de-
generation (AMD), are among the most common types of
retinal degeneration [3]. Inherited retinal diseases have been
associated with mutations in more than 200 different genes
(see http://www.sph.uth.tmc.edu/Retnet) [4, 5]. As a result,
the onset of hereditary disease and the speed of progression
can be highly variable. This contrasts with age-related macular
degeneration (AMD) which specifically affects older adults
and where dysfunction of photoreceptors is thought to be
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caused by cellular senescence of retinal pigment epithelium
cells (RPE), a photoreceptor support cell [6–8].
Compared with many other parts of the nervous system, the
eye represents a highly accessible and (at least partially)
immune-privileged system [9–11]. It is therefore unsurprising
that it has become a focus of significant translational research
efforts. Common to all vertebrate retinas is a highly stratified
structure, composed of three layers of cells connected by two
synaptic layers. The outer retina is composed of photosensi-
tive cone and rod photoreceptor cells, which form the outer
nuclear layer (ONL), connecting to interneurons including
bipolar, amacrine and horizontal cells in the inner nuclear
layer (INL) (Fig. 1). Notably, most forms of inherited retinal
diseases affect photoreceptors or their support cells (e.g.
RPE), resulting in photoreceptor death, but the inner retina
(i.e. bipolar, amacrine, horizontal and ganglion cells) remains
largely unaffected [3, 12, 13]. This makes the retina an
attractive recipient for novel therapeutic approaches including
gene and cell therapy and the use of implant devices.
Gene and Cell Therapies
Archetypal gene therapy aims to provide a normal copy of the
gene that is faulty by delivering it via a viral vector [14]. The
most effective vectors for retinal transduction are those based
on adeno-associated viruses (AAV). These vectors can medi-
ate efficient long-term gene transfer to both photoreceptors
and RPE. Recombinant AAV vectors can be constructed with
a number of different capsids (i.e. serotypes) that can lead to
transduction of different retinal cell types depending on route
of administration. AAVs are relatively small viruses with a
single-stranded DNA genome. They are non-pathogenic to
humans, and depending on their method of delivery, they
can penetrate deep into tissues providing very good levels of
Fig. 1 Schematic diagram depicting how CRISPR/Cas9 gene editing can
be harnessed for in vitro disease modelling and in vivo gene editing.
CRISPR/Cas9 gene editing panel: Cas9 nuclease in complex with a
gRNA can generate specific double-stranded breaks (DSB) in the host
DNA. Cell’s DNA repair mechanism will repair the DSB by either error-
prone NHEJ or error-free HDR. NHEJ-mediated gene editing will most
likely result in the introduction of insertions and deletions (indel, red
lines) that will lead to premature STOP codon formation. HDR-
mediated gene editing, in the presence of a homologous DNA template
(green lines), will introduce precise genomic changes in the host’s DNA.
Most popular CRISPR/Cas9 gene editing approaches are an RNP
approach, where Cas9 protein is complexed with gRNA for delivery,
and a plasmid approach, where Cas9 cDNA, gRNAs and a reporter are
usually overexpressed from one, two or more vectors. In vitro disease
modelling panel: Shows how fibroblasts can be sampled from healthy
and affected individuals and reprogrammed into human iPSCs. CRISPR/
Cas9 gene editing can then be used to introduce disease-causing
mutations of interest in healthy iPSCs or correct them in affected iPSCs
to generate isogenic iPS cell line pairs. These can then be differentiated to
photoreceptors for disease modelling purposes. In vivo gene editing:
cDNA containing Cas9 gene editing tool can be packed into AAV for
subretinal injection to target different populations of retinal cells. The
retina is a layered structure composed of three layers of cells connected
by two synaptic layers: the inner plexiform layer (IPL) and the outer
plexiform layer (OPL). At the outer most region, cone and rod
photoreceptor cells form the outer nuclear layer (ONL). The inner
nuclear layer (INL) is composed of bipolar, amacrine, horizontal and
Müller glia cells. Lastly, the inner most layer, the ganglion cell layer
(GCL) is comprised of retinal ganglion cells and displaced amacrine
cells. The optic fiber layer (OFL) contains retinal nerve fibers that exit
the eye through the optic nerve
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cellular transduction. In the retina, subretinal delivery is cur-
rently the route of administration of choice with serotypes
such as AAV5 and AAV8 providing highly efficient photore-
ceptor transduction. While the capacity of AAV vectors is
relatively small when compared to other viral vectors, with a
maximum capacity of approximately 5 kb of insert DNA, it is
large enough to accommodate most genes. In preclinical stud-
ies over the last 15 years, the utility of AAV vectors for gene
supplementation for recessively inherited degenerations has
been demonstrated in a number of animal models leading to
long-term phenotypic rescue [15, 16].
The success in preclinical development has led to a number
of phase I/II clinical trials to treat inherited retinal degenera-
tive diseases using gene therapy [17–23]. In the first trials,
patients carrying a defective RPE65 gene, which causes a
form of LCA, received a subretinal injection of an AAV vector
carrying a human RPE65 complementary DNA (cDNA) un-
der the control of either a human RPE65 promoter [17] or a
ubiquitously expressed actin promoter [20, 23]. In each case,
subretinal delivery of an AAV vector in patients was shown to
be safe. Additional findings included improvement of visual
function, although these improvements varied between pa-
tients and were modest overall. More recent reports have fur-
ther demonstrated efficacy but have also underlined the im-
portance of achieving the correct levels of gene expression for
robust and sustained rescue [24–26]. Despite the success of
these trials, a gene supplementation approach has its limita-
tions; in particular, it requires the presence of the affected cells
and is most effective in the early stages of disease progression.
Another limitation is the length of the cDNA that the AAV can
package for delivery [27–30], which prevents replacement of
very large genes, such as ATP-binding cassette subfamily a
member 4 (ABCA4, ∼7.3 Kb), which causes Stargardt disease
[31, 32] and centrosomal protein of 290 kDa (CEP290,
∼7.9 kb) which causes another form of LCA [33]. Moreover,
it can only be used for single-gene defects involving a known
gene.
Stem Cell-Derived Photoreceptors
Cell replacement therapy offers a therapeutic approach for pa-
tients with advanced disease where there has been extensive
photoreceptor loss. It may also permit treatment of conditions
with non-genetic or unknown cause. We, and others, have car-
ried out a variety of studies in the area of photoreceptor deri-
vation and transplantation. Ground-breaking work on murine
embryonic stem cells (ESCs) by Sasai and colleagues [34•]
showed that ESCs cultured in 3D suspension in the presence
of matrices, such as Matrigel, spontaneously form self-
organising embryoid bodies that support the morphological
differentiation of retinal cells. This so-called 3D culture tech-
nique has since been shown to sustain the differentiation of
murine photoreceptors up to equivalents of the first postnatal
week [35]. We, and others, have shown that donor photorecep-
tor cells from early mouse postnatal retina as well as ESC-
derived mouse photoreceptor precursors can be transplanted
into the degenerative retinas of adult mice [35–43]. Following
transplantation, if present in sufficient numbers, these cells are
capable of restoring aspects of visual function [42, 44–47].
Several laboratories have also described the derivation of pho-
toreceptors from human ESCs and iPSCs [48–54, 55•, 56••].
Canto-Soler and colleagues were the first to show human plu-
ripotent stem cells (hPSCs)-derived retinal organoid containing
photoreceptors that bear key photoreceptors structures and are
responsive to light in vitro [56••]. Their protocol uses a 3D to
2D to 3D multi-stage cell culture differentiation process that
takes advantage of the ability of hPSCs to spontaneously dif-
ferentiate towards the ectoderm pathway under neural induc-
tion culture conditions. In this protocol, unlike previous neuro-
differentiation approaches [57–59], typically costly SMAD in-
hibitors are avoided in the neural induction process. Instead,
hPSCs are allowed to form embryoid bodies (EBs) in suspen-
sion, then allowed to grow in a monolayer until Bhorseshoe^-
shaped neural retinal-like structures appear spontaneously.
These can then be dissected manually and cultured in suspen-
sion for up to 27 weeks to form mature retinal organoids. This
hPSCS retinal differentiation protocol has an initial 3D to 2D
step as others have previously described [48, 52, 53]. Among
the advantages of these protocols is the ability to control the
starting number of cells and, therefore, reduced initial variabil-
ity. However, issues may arise when the resulting EBs are then
grown on a 2D monolayer to further develop, as the presump-
tive neural retina structures are dissected manually. This ap-
pears to be a key stage in variability between different labora-
tories using the same protocol, as the criteria used to define the
presumptive neural retinal structures is subjective. Canto-Soler
and colleagues found that photoreceptors start to express ma-
ture markers, such as Rhodopsin, S-Opsin and LM-opsin, by
week 17 and that these photoreceptors demonstrate light sensi-
tivity by week 27. Goureau and colleagues on the other hand,
used a simpler 2D to 3D cell culture system, where human
iPSCs cells are allowed to become confluent on a monolayer,
prior to neural induction [55•]. They take advantage of the
cells’ ability to self-form into neural retinal-like structures even
within the 2D cell culture conditions; these could then be dis-
sected and further differentiated in 3D suspension, going on to
correctly express many markers of retinal commitment and
even opsin expression. While this protocol demonstrates a sim-
pler way to differentiate iPSCs to neural retina, it failed to
support the morphological differentiation of photoreceptors,
including the formation of outer segments (OS), as described
by Canto-Soler and colleagues [56••]. However, while Canto-
Soler’s protocol supported Opsin expression and light sensitiv-
ity of hPSC-derived photoreceptors, the transmission electron
microscopy (TEM) data showed little evidence of mature OS
formation. Recently, we have adapted some of the protocols
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described previously and have found that it is possible to gen-
erate short OS-like structures from hESC-derived retinal
organoids (Gonzalez-Cordero et al., in preparation). A recent
report by Takahashi and colleagues showed that transplantation
of immature hPSC-derived photoreceptors into the subretinal
space of nude rats allows for the subsequent formation and
maturation of OS structures [60••]. This suggests that the
hPSC-derived photoreceptors described to date may all have
the capacity to form OS but lack sufficient instruction or sup-
port from the in vitro environment to be able to do so.
A major issue currently limiting the widespread utility of
hPSC-derived cells is the variability in efficiency between pro-
tocols and even the reproducibility of the same protocol by
different laboratories. There are many potential variables that
may be introduced, including the cell line used and its passage
number, the different batch numbers of commercially produced
reagents used and the subjective choice of neural retina resem-
bling structures. Robust methods of quantifying the purity and
viability, as well as the developmental stage, of photoreceptors
will be important. As a step towards this, we, together with
Sowden and colleagues, have used cluster of differentiation
(CD) cell surface markers to quantify and purify stage-specific
photoreceptors in mouse ES-derived photoreceptors and mouse
and human retinal samples [40, 61]. Among these, CD73 allows
for the enrichment of rod precursor cells [38, 40, 61].
Furthermore, pilot experiments using human retinal samples
indicated that a similar CD panel could be used to assess and
quantify the maturation stage of hPSC-derived photoreceptors,
especially since human iPSC-derived photoreceptors and adult
human retina are reported to express CD73 [55•, 61]. This ap-
proach, if successful in conjunction with human retinal
organoids, may be useful for cell therapy purposes, as it circum-
vents the use of reporter markers in transgenic hPSC lines that
cannot be used clinically. A CD panel could also be a good way
to characterise and quantify the extent of retinal differentiation in
individual batches, since previous studies have demonstrated
that different hPSCs differentiate along the retinal lineage with
varying efficiencies and with the resulting retinal cells almost
always co-existing alongside non-retinal cells [48, 52, 54,
62–64]. An additional point to note is the need to develop robust
criteria for defining what constitutes commitment of the stem
cell to differentiate into a given cell type. At present, the field
relies heavily on the presence/absence of various photoreceptor-
specific proteins, typically assessed by immunocytochemistry.
We have already shown that such methods of assessment can
lead to erroneous conclusions about howwell a cell has adopted
a given fate [43] and therefore it will be important to assess the
derived cells with greater thoroughness, using other assays such
as RNAseq, morphology and functionality.
A challenge when differentiating human ES or iPSCs to
retinal neurons using 3D culture methods is that, like mouse
ES retinal differentiation, human ESC/iPSC retinal differenti-
ation follows a time course similar to that of normal
development, which for the human organoids is many months
(Gonzalez-Cordero et al., in preparation); this leads to a large
proportion of differentiated organoids becoming necrotic. This
is a major hurdle, since photoreceptor OSs form late in devel-
opment and need long periods of cell culture to form
(Gonzalez-Cordero et al., in preparation). Recent findings from
related ESC disciplines suggests that upgrading from the clas-
sic cell culture plate differentiation approach to the use of bio-
reactors can improve differentiation and viability, providing
cells with improved aeration and distribution of nutrients, as
well as apparently encouraging formation of 3D structures
[65–68]. Preliminary work in our group suggests that bioreac-
tor technology may represent a stepping stone to upscaling the
cell culture process for therapeutic applications, together with
the ability to improve the survival and abundance of mature
photoreceptors (Ovando-Roche et al., in preparation).
Regardless of these challenges, however, it is clearly pos-
sible to generate functional photoreceptors from hPSCs. This
raises the question of how best to use these advances to model
retinal disease in vitro.
Using Human Pluripotent Stem Cells as Retinal
Disease Modelling Tools
The inability of animal models to reflect human disorders
accurately may have contributed to disappointing outcomes
in many clinical trials of drugs and therapies. The revolution
in somatic cell reprogramming that has enabled the generation
of human iPSCs from adult tissue [69], coupled with recent
advances in genome-editing technology [70–72], now allows
us to investigate cellular aspects of human neurodegenerative
disease in vitro. This not only potentially circumvents the
dependence on scarce primary patient tissue and animal
models to develop a therapy but may also facilitate a patient-
tailored approach. We can now derive human iPSCs from
patients and differentiate these into various tissues to model
some aspects of disease in vitro [73•, 74]. Not only do these
cells offer the opportunity to model cellular phenotypes but
also provide a platform for high throughput drug screening
and cell transplantation studies.
While it is not possible to model all aspects of a condition
using iPSC-based disease modelling, it can be a very powerful
tool for investigating cellular pathology. A major limitation,
however, is the differentiation and phenotypic variability that
is observed even in human iPSCs derived from the same do-
nor [75, 76]. This is exacerbated further when comparing be-
tween unrelated hPSC lines. Even if the cellular phenotype of
a given mutation is strong and highly penetrant, it may be lost
due to genetic and epigenetic background differences [75–79].
A powerful approach to overcome this hurdle is to use gene
editing tools that enable precise editing of endogenous hPSC
genomic sequences [80]. In this scenario, gene editing can be
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used to correct the disease-causing mutation in a patient-
derived iPSC line to generate a pair of isogenic iPSC lines
that differ only in the disease-causing mutation, providing a
less variable and more faithful disease modelling system.
Alternatively, the same technology could be used, for exam-
ple, to insert disease-causing monogenic mutations in unaf-
fected hPSCs to generate isogenic pairs for disease modelling.
The former option has the advantage that for recessive dis-
eases only one allele needs to be repaired, whereas the latter
strategy would need both alleles to be mutated. However, the
latter approach would have the added advantage of reducing
costs and research time, as obtaining patient samples and gen-
erating iPSCs is both costly and time consuming. These gene
editing strategies will prove invaluable for studying human
biology and disease.
In one of the first human iPSCs studies to model retinal
disorders, Gamm and colleagues focused on Best disease, an
inherited retinal dystrophy of the macula that leads to progres-
sive and irreversible central vision loss [81]. In this disease,
mutations in the RPE gene bestrophin 1 (BEST1) result in an
accumulation of waste products from shed photoreceptor OS
in the RPE cells, resulting in RPE dysfunction and secondary
photoreceptor death. In this study, human iPSCs were derived
from both patients and their unaffected siblings and differen-
tiated into functional RPE cells. Affected iPS cell-derived
RPE cells displayed delayed rhodopsin protein degradation
after photoreceptor OS phagocytosis, compared to unaffected
iPS cell-derived RPE. These findings indicated, for the first
time in a human iPS cell-derived RPE cell, that BEST1 muta-
tions cause defective photoreceptor OS handling [81]. In an-
other iPS disease modelling study, Stone and colleagues
modelled disease resulting from usherin (USH2A) mutations,
which lead to autosomal recessive RP [82]. They derived
iPSCs from a patient with a USH2A mutation and differenti-
ated the resulting cells towards a photoreceptor fate, compar-
ing their results to unrelated, unaffected iPSC-derived photo-
receptors. The patient-derived USH2A mutant photoreceptors
had upregulation of GRP78 and GRP94, suggesting that mu-
tations in USH2A can cause endoplasmic reticulum stress,
which occurs frequently in neurodegenerative diseases [82].
In a study by Cheetham and colleagues, iPSCs derived from a
healthy individual and a patient bearing an LCA-causing mu-
tation inCEP290were differentiated into fibroblasts, RPE and
photoreceptors [83]. They found that CEP290-LCA-derived
fibroblasts and photoreceptors showed a reduction in the num-
ber of ciliated cells, as well as cilia length, in line with the fact
that CEP290 has been shown to be important in regulating
cilia assembly and development [84, 85]. The phenotype
could be rescued by treating the CEP290-LCA cells with an-
tisense morpholino oligonucleotides, which blocked the aber-
rant splicing of CEP290 [83].
The first reported studies demonstrate the potential of iPSC
retinal disease modelling. However, there are some key issues
to consider when interpreting the results and setting up future
studies. Robust methods of quantification and, ideally, a com-
parison of several cell lines should be used; this is of even
greater importance when isogenic controls are not available.
The high variability in differentiation capacities between dif-
ferent ESCs and/or iPSCs is well documented. Even when
retinal organoids are derived from the same iPSC line at the
same time and are cultured under the same conditions, they
can reach maturity at different times. In addition, some
organoids may fail to differentiate completely, while others
differentiate successfully. Such differences may arise because
each organoid is likely to have different cell type content and
cell-to-cell interactions. In light of such variations, comparing
subtle phenotypic changes may be problematic. Repeated
batch differentiation, coupled with robust quantification ap-
proaches, such as western blotting, qRT-PCR and/or
RNAseq and FACS analysis will be key to obtaining mean-
ingful and consistent results. These approaches will allow
analysis of specific cell types instead of whole organoid anal-
ysis, where variation in cellular composition may create or
obscure a phenotype. Variability can also be minimised by
using optimal controls. For example, Gamm and colleagues
used iPSCs derived from unaffected siblings as controls [81].
While the siblings may not have an identical genetic and epi-
genetic make-up, it is a more reliable comparison than com-
paring iPSC-derived retinal organoids from two unrelated in-
dividuals as used in the other studies described here [82, 83].
The optimal control, especially if the disease to be modelled is
not highly penetrant, would be the same patient-derived iPSC
line but gene edited to correct the disease-causing mutation
(i.e. isogenic pairs). Unfortunately, the gene editing technolo-
gy required to generate such isogenic controls with relative
ease, CRISPR/Cas9 gene editing, has only been available for
the past 4 years [70–72].
Stem Cells and Gene Editing
Genome editing technologies have been in the field since the
1990s (reviewed in [80]). Site-specific nucleases including
zinc fingers (ZFN), transcription activator-like effectors
(TALENS) and Cas9 proteins allow the introduction of precise
double-strand breaks and gene modifications within the ge-
nome. Once one of these nucleases generates a DNA cut, the
cell’s DNA repair mechanism is activated to avoid cell death,
repairing the DNA break either by (error-prone) non-
homologous end joining (NHEJ) or by (error-free)
homology-directed recombination (HDR) (Fig. 1) [86–92].
NHEJ-mediated gene editing typically leads to the introduc-
tion of insertions and deletions (indels) in the genome,
resulting in frameshift mutations that will disrupt full-length
protein production through generation of a stop codon or re-
sult in a gene knockout, depending where the nucleases have
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created the DNA cut. On the other hand, HDR-mediated gene
editing, in the presence of a homologous DNA template, can
be used to modify the target DNA area with high precision. In
the disease modelling context, the power of HDR-mediated
gene editing can be harnessed by transfecting cells with vec-
tors encoding one of these nucleases together with an
engineered homologous DNA template that contains the de-
sired genetic change (Fig. 1). While ZFN and TALENS are
highly customizable DNA-binding proteins and can be
harnessed to drive sequence-specific DNA targeting
[93–96], engineering these proteins to bind to specific DNA
targets, as well as achieving their robust delivery for this pur-
pose, can be laborious and technically challenging [97]. By
contrast, Cas9 nucleases are guided by two short sequences of
RNA, a specificity-determining guide RNA sequence,
CRISPR RNA (crRNA), and a transactivating crRNA
(tracrRNA), which serves as scaffold for the Cas9 protein to
form a complex (i.e. a protein:RNA complex) that forms
Watson-Crick base pairs with the complementary DNA target
sequence, resulting in a site-specific double-strand break [71,
72, 98] (Fig. 1). Advances in the field of CRISPR/Cas9 have
rapidly led to the establishment of engineered Cas9 plasmid-
based systems, where a Cas9 can be combined with a single
ch ime r i c gu ide RNA (gRNA) , a fu s ion o f the
tracrRNA:crRNA duplex, for genome editing in eukaryotic
cells at any genomic locus of interest [99–101]. While the
CRISPR/Cas9 system is easier to use than its previous coun-
terparts (i.e. TALENS and ZFN), some key issues still remain
with regard to HDR-mediated gene editing, these include
Cas9 plasmid integration, off-targeting and gene editing effi-
ciency. For example, choosing between a plasmid-based ap-
proach or a ribonucleoprotein (RNP) CRISPR/Cas9 approach,
where Cas9 protein forms a complex with synthetic gRNA
[102, 103], is a key decision as each has different advantages
and disadvantages. In the case of precise HDR-mediated gene
editing for human iPSC disease modelling, either approach
could be used. Plasmid-based gene editing allows for reporter
expression which, unlike an RNP approach, will allow enrich-
ment for the population containing the Cas9 gene editing
toolkit. The use of an all-in-one plasmid approach where the
reporter (e.g. puromycin or enhanced green fluorescence pro-
tein, EGFP), Cas9, gRNAs and repair template (i.e. donor
template for HDR-mediated repair) are present on a single
vector [100, 104] is also advantageous, as it provides obvious
delivery advantages over a two or three plasmid system,
where a given target cell may not receive all necessary plas-
mids to carry out gene editing. However, it is important to take
into consideration the reporter or selection marker of choice as
up to 30% plasmid background integration has been reported
to occur when using a drug resistance cassette [105]. In some
studies, use of fluorescent reporters such as EGFP may be
preferable as FACS sorting could be used to isolate the
EGFP-positive cell population (i.e. transduced cells) and,
upon repeated passaging, to isolate the EGFP-negative popu-
lation (i.e. transduced and free of plasmid integration). The
disadvantages of using a plasmid approach, however, include
that the plasmid will take 6–12 h to express the Cas9 gene
editing tool kit, and it will remain in most cells for over 72 h,
which means the Cas9 will remain active during this time,
making off-targeting more likely [102]. If CRISPR/Cas9 gene
editing is used for clinical applications, detailed evaluation of
undesirable off-target modifications will be essential. Since
mismatches at the 5′ end of the gRNAs are tolerated, the use
of the wild-type Cas9 can lead to unintended off-target effects
[106–108]. To address this issue, investigators have
engineered modified or Bevolved^ Cas9 proteins [109, 110].
Among these, Cas9 nickase (Cas9n) carries a catalytic amino
acid substitution (D10A) in the conserved RuvC nuclease do-
main, which converts this enzyme into a nickase meaning that
Cas9n can only cleave one strand of DNA [110]. With this
enzyme, the two gRNAs that are adjacent on opposite strands
of the target site, coupled with two Cas9n molecules, would
reduce off-targeting in two ways. First, since single-strand
breaks are quickly repaired by the error-free base excision
repair mechanism, genome integrity is maintained [111].
Second, off-targeting is greatly reduced by the two gRNAs
that the Cas9n system needs to generate a double-strand break,
since the likelihood of the two different gRNAs being com-
plementary to other regions of the genome and close enough
to each other to drive Cas9n-based cleavage is very low. Using
the Cas9n system, Zhang and colleagues found that off-
targeting was reduced 50–1500-fold. An additional approach
to reduce off-targeting is to shorten the length of the gRNAs;
this may reduce Cas9 activity but it greatly reduces off-targets
mutations [106, 108].
The Cas9n RNP approach is an alternative way to gene edit
using the CRISPR/Cas9 system for in vitro disease modelling.
This method circumvents the problem of integration in plasmid-
based systems and significantly reduces off-targeting, since the
Cas9 RNP complex is rapidly degraded in cells within 24 hwhen
delivered directly [102, 103]. This means that DNA breaks
would occur for a shorter period of time and since there is no
plasmid in this approach, there is no risk of integration.
Furthermore, unlike the plasmid approach, since the Cas9 RNP
is an active nuclease complex, it starts to gene edit as soon as it is
transfected into the cells. Cas9 RNP approaches have been
shown to be highly efficient in introducing indels and HDR-
mediated precise gene edits [102, 103], although to our knowl-
edge an all-in-one plasmid vs RNP approach has not been direct-
ly compared for the same target gene using the same gRNAs.
The importance of generating isogenic iPSC line pairs has
been discussed earlier. Jaenisch and colleagues showed that
gene editing can be used to generate isogenic pairs (e.g. af-
fected and repaired) from human iPSCs or ESCs, leading to
two cell lines that have the same genetic and epigenetic back-
ground and differ only in the disease-causing mutation [112].
Curr Stem Cell Rep (2017) 3:112–123 117
In this study, ZFNs were engineered to target the α-synuclein
(SNCA) locus, a gene commonly mutated in Parkinson’s dis-
ease. Using different gene editing strategies, they introduced
two common mutations of SNCA in unaffected ESCs or
corrected the mutation in a patient-derived iPSC line [112].
Co-electroporation of the ZFN expression plasmids and donor
constructs, followed by selection of the transfected cells, led to
a genome editing efficiency of ∼0.9% (3 out of 336 screened
clones where targeted at the correct locus). Furthermore, using
a positive and negative selection approach, they obtained a
maximum efficiency of ∼22% (9 out of 41 screened clones
correct for the desired mutation). The resulting cells were
karyotypically normal, maintained pluripotency and were able
to differentiate into dopaminergic neurons [112]. This study
represents one of the first reports of patient-derived iPSCs and
wild-type human ESCs being gene edited to create isogenic
pairs for disease modelling. This not only represents a signif-
icant progress for in vitro disease modelling but also a major
advancement towards human iPSC-based cell replacement
therapies.
In the context of in vivo applications in the retina, an RNP
approach may not be the most suitable, as achieving efficient
delivery of the RNP complex into retinal cells may prove
difficult. Given the proven efficacy of viral vector-mediated
gene transfer to the retina, a gene-based approach, where the
Cas9 tool kit is packaged in an AAV vector, may be easier.
However, AAV vectors can only package approximately
∼5 Kb of insert and the Streptococcus pyogenes Cas9
(SpCas9) DNA is about 4.2 Kb, leaving little or no room for
a reporter or gRNA and repair template. Different approaches
have been taken to overcome this problem in other cell types.
Zhang and colleagues used a dual AAV system approach to
deliver SpCas9 and gRNAs to disrupt gene function in divid-
ing mouse brain cells in vivo [113]. The same group later
demonstrated that using the SpCas9 orthologue,
Staphylococcus aureus Cas9 (SaCas9), which is 3.2 Kb and
therefore approximately 1 Kb smaller than SpCas9 can be
packaged into a single AAV system along with gRNAs and
can introduce high levels of gene disruption in mouse liver
cells in vivo [114]. Similarly, SaCas9 has been used in both a
dual and a single AAV system, with various gRNAs, to target
mouse muscle cells in vivo [115]. Recently, Hewitt and col-
leagues attempted a dual AAV2 CRISPR/Cas9 system ap-
proach for disrupting the expression of yellow fluorescent
protein (YFP) in retinal ganglion cells of a Thy1-YFP trans-
genic mouse model [116]. They managed to reduce the num-
ber of YFP-positive cells by 84%, apparently without affect-
ing normal retinal function. This proof-of-concept study for
NHEJ-based gene editing in the retina, together with the
in vivo AAV-based gene editing studies in other tissues, sug-
gests that in vivo retinal gene editing may be achievable at
efficiencies high enough for in vivo retinal therapy in the
future (Fig. 1). While using AAV to deliver the necessary
CRISPR components for efficient gene editing is challenging
due to size constraints, other viral vectors are able to accom-
modate larger DNA inserts. Lentiviral vectors, for example,
can package approximately 9 kb of insert DNA that would be
large enough to accommodate both a large Cas9 nuclease (e.g.
SpCas9) and the gRNA cassettes. One such approach has been
used to carry out gene editing in RPE cells whereVEGF-Awas
disrupted in vitro in human cells [117]. A similar approach
could be used in vivo for targeted gene disruption in the RPE
but not for targeting photoreceptor as lentiviral vectors do not
transduce these cells efficiently. However, a major problem
that still remains to be addressed is how to achieve efficient
and accurate HDR-based gene editing in the retina if most of
its cells are post-mitotic and largely lack HDR repair.
Together, these studies suggest that disease modelling of a
variety of inherited retinal diseases using iPSCs is a realistic
prospect. However, the appropriate choice of control cell line
and gene editing tool kits to detect subtle phenotypic changes
in affected cell types will be critical for successful disease
modelling. Regarding in vivo gene editing in the retina, pack-
aging the whole CRISPR/Cas9 gene editing tool kit in a single
AAV vector for delivery will likely lead to the highest levels of
transduction efficiency and gene disruption in the retina.
However, an efficient method to carry out precise DNA sub-
stitutions in post-mitotic retinal cells remains to be elucidated.
Summary and Future Challenges
hPSCs represent a powerful tool for understanding human ret-
inal development, retinal disease modelling, drug discovery
and for developing cell transplantation therapies. However, to
achieve these successfully, it is necessary to consider a number
of requirements. A significant amount of further work is re-
quired to establish robust and reproducible protocols for the
efficient generation of retinal organoids from hPSC sources. Of
particular importance is the ability to generate fully mature
hPSC-derived photoreceptors including OS in vitro. This
may necessitate the use of bioreactors, co-cultures of RPE cells
and/or the use of bioscaffolds. Faithful disease modelling will
benefit from the use of isogenic pairs of iPSC lines, as well as
robust photoreceptor quantificationmethods and improved ret-
inal organoid differentiation. Reducing the variability between
differentiations remains a major challenge. Generating isogen-
ic controls for the affected cell type should significantly reduce
the inherent variability that is introduced by differences in epi-
genetic and genetic background when using iPSCs from dif-
ferent sources. Methods to assess the phenotype should be
quantitative and robust. Patient-specific iPSCs are not only a
powerful tool for disease modelling for inherited retinal degen-
eration but may in the future also become a source of cells for
photoreceptor transplantation. Two key aspects we need to
consider for cell transplantation studies are the optimal
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developmental stage of the iPSC-derived retinal tissue to trans-
plant [35, 41, 118], and the genetic correction of the patient’s
affected cell type before delivery. Recently, a CD surfacemark-
er panel was described for murine ESC-derived photorecep-
tors. This panel allowed for the isolation and purification of rod
photoreceptor cells at the optimal stage of development for
transplantation [40, 61]. Promising preliminary studies in hu-
man retinal tissue further indicated that a similar panel should
be identifiable for hPSC-derived retinal tissue [61], opening
the way to isolating photoreceptors for cell transplantation
therapies in humans. If iPSCs from patients are to be used as
the donor source, it will also be necessary to repair the inherited
defect prior to transplantation. CRISPR/Cas9 gene editing is
likely to play a key role here. For clinical use, a RNP CRISPR
Cas9n gene editing approach is likely to be most advanta-
geous, as it offers high gene editing efficiency and minimum
off-targeting effects. A stringent screening of the resulting iPS-
derived photoreceptors will be required prior to transplanta-
tion; karyotyping, tumorigenicity and whole genome sequenc-
ing screens will be necessary to ensure safety in phase I clinical
trials. Takahashi and colleagues initiated the first human RPE
iPSC-derived phase I clinical trial for neovascular AMD in
2014. The first subject in the trial received autologous iPSC-
derived RPE, while subsequent subjects received allogenic
iPSC-derived RPE. While several studies have recently shown
that hESC-derived RPE cells are safe following transplantation
into patients in phase I clinical trials [119–121], some concerns
were raised in the study by Takahashi and colleagues about the
stability of the genome of the iPSC-derived RPE cells used for
sheet transplantation, causing the trial to be temporarily halted.
Regardless, this landmark study served as proof-of-principle to
show that iPSC-derived cell therapy in humans is possible.
The major advantage of patient-specific, gene-corrected, au-
tologous iPSC-derived cells over hESC-derived cells is reduced
immunogenicity following transplantation. However, develop-
ing clinical-grade autologous iPSC-derived cells for each indi-
vidual is likely to be prohibitively expensive for the foreseeable
future and alternative strategies are therefore required. In an ef-
fort to address this issue, Takahashi and colleagues have recently
shown that non-human primate iPSC-derived RPE, transplanted
into allogenic major histocompatibility complex (MHC)-
matched animals, survived without evidence of rejection while
iPSC-derived RPE transplanted into MHC-mismatched animals
resulted in immune rejection [122••]. Furthermore, Shinja
Yamanaka, Nobel Prize winner for his discovery on iPSCs, is
developing a bank of clinical grade iPSC lines that are homozy-
gous for the common Japanese MHC types. This should allow
MHC-matched patients to be treated with the same iPSC source,
greatly reducing costs and variability of differentiation.
HDR-mediated gene editing in vivo may have potential in
the future to treat inherited retinal degenerations, particularly
those caused by dominant mutations. Successful in vivo gene
disruption via NHEJ using CRISPR/Cas9 in anAAV system has
been shown in several tissues. However, HDR-mediated gene
editing for precise DNA modifications in post-mitotic neurons
remains to be achieved. If HDR-mediated gene editing in post-
mitotic retinal cells is achieved using a single AAV system,
another aspect to consider will be the requirement to use an
inducible CRISPR/Cas9 systemwhere induction of gene editing
can be stimulated with a drug and consequently switched off
after correction, since long-term expression of Cas9 system
could lead to an increase off-targeting of the genome.
Regardless of the undoubted ahead challenges, these are
exciting times and the landmark studies discussed in this re-
view open the door to widespread application of hPSC-based
technology and gene editing to advance our understanding
and treatment of retinal disorders.
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